Dextera Biosciences
Greg Went is a highly experienced executive in the biosciences industry. Greg currently holds the position of Chief Executive Officer and Chairman at Dextera Biosciences. With a background in Chemical Engineering, Greg co-founded and led various companies such as SynaVir, Adamas Pharmaceuticals, Inc., Tethys Bioscience, Inc., DNA Sciences, and CuraGen Corporation. Their expertise includes genomics, DNA detection, bioinformatics, and business development. Greg's leadership has been instrumental in creating successful partnerships and driving internal R&D programs within the companies Greg has been involved with.
This person is not in any teams
This person is not in any offices
Dextera Biosciences
Dextera Biosciences is developing a new category of drugs, Synthetic D-Proteins, to overcome the limitations of current drug modalities. Synthetic D-Proteins exhibit antibody-like specificity to a single therapeutic target but with the broad distribution of small molecules, all while being otherwise “invisible” to the rest of the body. The consequences are that we can deliver sustained antibody-like activity specifically to interstitial targets, enable oral delivery with complete metabolic stability, and extend therapeutic durability with no immunogenicity. We are focusing on debilitating diseases where significant unmet need remains due to the limitations of current drugs.